Copyright
©The Author(s) 2025.
World J Hepatol. Jan 27, 2025; 17(1): 96105
Published online Jan 27, 2025. doi: 10.4254/wjh.v17.i1.96105
Published online Jan 27, 2025. doi: 10.4254/wjh.v17.i1.96105
Cluster ID | Size | Silhouette | Mean year | Label (LLR) |
0 | 172 | 0.825 | 2013 | Cell-based therapy |
1 | 164 | 0.833 | 2007 | Tetrachloride-induced liver fibrosis model |
2 | 162 | 0.743 | 2017 | Mesenchymal stem cell therapy |
3 | 132 | 0.792 | 2009 | Liver fibrosis |
4 | 119 | 0.902 | 2018 | Extracellular vesicle |
5 | 95 | 0.937 | 2003 | Hepatic fibrogenesis |
6 | 69 | 0.896 | 2021 | Drugs intervention |
7 | 23 | 0.983 | 2017 | Severe alcoholic hepatitis |
8 | 22 | 0.991 | 2002 | Systemic infusion |
9 | 18 | 0.967 | 2017 | Cellular mechanism |
10 | 14 | 0.977 | 2010 | Thioacetamide-induced cirrhotic rat model |
- Citation: Zhu WY, Li X, Xie JL, Lu Q, Ma YJ, Zhu ZJ, Liu J. Hotspots and trends in stem cell therapy for liver fibrosis and cirrhosis: A bibliometric analysis. World J Hepatol 2025; 17(1): 96105
- URL: https://www.wjgnet.com/1948-5182/full/v17/i1/96105.htm
- DOI: https://dx.doi.org/10.4254/wjh.v17.i1.96105